A Prospective Study on Predicting the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PET/CT in the evaluation of treatment response to neoadjuvant chemotherapy(NAC) for patients with locally advanced gastric cancer(LAGC).
• Age between 18-75 years.
• Histologically confirmed gastric adenocarcinoma through gastroscopy.
• Resectable gastric cancer.
• ECOG performance status 0-1.
• White blood count \>4x109/L, Absolute neutrophil count (ANC) \>2x109/L, Hemoglobin (Hb)\>90g/L, Platelets \>100x109/L.
• Ejection Fraction\>50%.
• Serum bilirubin \<1.5x ULN; ALT and AST \<1.5x ULN.
• Serum creatinine ≤1.5x ULN, or GFR\> 60ml/min.
• Agreement to participate in this study with informed consent form.
⁃ Willingness and ability to comply with the protocol for the duration of the study.
⁃ No children bearing petential in the next six months before enrollment.